Zacks Gives Neutral Rating to CONMED (CNMD)

By admin | 6 years ago

CONMED (NASDAQ: CNMD)‘s stock had its “neutral” rating restated by Zacks in a report issued on Wednesday. They currently have a $27.00 target price on the stock.

CONMED opened at 26.85 on Wednesday. CONMED has a 1-year low of $20.51 and a 1-year high of $31.94. The company has a market cap of $759.6 million and a price-to-earnings ratio of 440.16.

CONMED last released its earnings data on Thursday, April 26th. The company reported $0.43 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.44 by $0.01. The company’s revenue for the quarter was up 5.9% on a year-over-year basis. On average, analysts predict that CONMED will post $0.40 earnings per share next quarter.

Separately, analysts at CL King upgraded shares of CONMED from a “neutral” rating to a “strong-buy” rating in a research note to investors on Monday, May 14th.

CONMED Corporation (CONMED) is a medical technology company with an emphasis on surgical devices and equipment for minimally invasive procedures and monitoring.

About the author